A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia

NCT00791232 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: extended-release (ER) OROS paliperidone

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.